AIBullishCrypto Briefing · 4h ago7/10
🧠
Absci Corporation progresses ABS-201 into human trials, bolstering AI-driven drug discovery
Absci Corporation has advanced its AI-driven drug candidate ABS-201 into human clinical trials, marking a significant milestone in the application of artificial intelligence to pharmaceutical development. This progression demonstrates that AI-accelerated drug discovery can compress traditional development timelines, potentially reshaping how biotech companies approach drug development and reducing time-to-market for new therapies.
